Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mark Edward Rempala"'
Autor:
Mark Edward Rempala, Tom Raub, Carlos Mateos, Sehila Pleite, Josh Clayton, William J. Ehlhardt, Huaxing Pei, Bradley Condon, Stephanie L. Stout, Sheela Ashok, Sandaruwan Geeganage, Mei Lai, Burkholder Timothy P, Deidre Michelle Johns, Yong Wang, Kenneth James Junior Henry, Saravanan Parthasarathy, Zhohai Lu, Oscar de Frutos, Pablo A. García
Publikováno v:
Bioorganicmedicinal chemistry letters. 28(10)
During the course of our research efforts to develop potent and selective AKT inhibitors, we discovered enatiomerically pure substituted dihydropyridopyrimidinones (DHP) as potent inhibitors of protein kinase B/AKT with excellent selectivity against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::107b14709d1a2c2930c8a82be7b68c7d
https://pubmed.ncbi.nlm.nih.gov/29655979
https://pubmed.ncbi.nlm.nih.gov/29655979
Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F
Autor:
C Halstead, K M Heinz-Taheny, W Shen, Huaxing Pei, Liandong Ma, Louis Stancato, Celine Pitou, Emiko L. Kreklau, Gillig James Ronald, Baohui Zhao, Burkholder Timothy P, L J Heinz, R J Evans, Yong Wang, John Strelow, Michele Dowless, Michele C. Smith, Saravanan Parthasarathy, Laura J. Bloem, Richard A. Walgren, Mark Edward Rempala, Joshua Ryan Clayton, Phillip W Iversen
Publikováno v:
Blood Cancer Journal
Owing to the prevalence of the JAK2V617F mutation in myeloproliferative neoplasms (MPNs), its constitutive activity, and ability to recapitulate the MPN phenotype in mouse models, JAK2V617F kinase is an attractive therapeutic target. We report the di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b46cb5916bce43d323267c3a3bb27821
https://pubmed.ncbi.nlm.nih.gov/23584399
https://pubmed.ncbi.nlm.nih.gov/23584399
Autor:
David Anthony Barda, Yan Hao, Jacqueline K Akunda, Liandong Ma, Joshua Ryan Clayton, John Monte Knobeloch, Mclean Johnathan Alexander, Burkholder Timothy P, Denis J. McCann, Laura J. Bloem, David K. Clawson, Mark T. Uhlik, Eileen L. Considine, Manuel Vincente Sanchez-Felix, Mark Edward Rempala, David Mendel, Yuefeng Chen, Michael Lahn, James J. Starling, Henry James Robert
Publikováno v:
Investigational new drugs. 30(3)
LY2457546 is a potent and orally bioavailable inhibitor of multiple receptor tyrosine kinases involved in angiogenic and tumorigenic signalling. In biochemical and cellular assays, LY2457546 demonstrates potent activity against targets that include V
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c6912ded81b788baae3eb76114eb5ec
https://pubmed.ncbi.nlm.nih.gov/21360050
https://pubmed.ncbi.nlm.nih.gov/21360050